A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome

被引:18
作者
Barthel, Friederike M-S. [1 ]
Royston, Patrick [2 ]
Parmar, Mahesh K. B. [2 ]
机构
[1] GlaxoSmithKline Inc, Oncol R&D, London, England
[2] MRC Clin Trials Unit, London, England
基金
英国医学研究理事会;
关键词
st0175; nstage; nstagemenu; multiple arms; randomized controlled trial; survival analysis; surrogate marker; multistage trial; OVARIAN-CANCER; CYCLOPHOSPHAMIDE; PACLITAXEL; CISPLATIN;
D O I
10.1177/1536867X0900900401
中图分类号
O1 [数学]; C [社会科学总论];
学科分类号
030301 [社会学]; 070101 [基础数学];
摘要
We present menu- and command-driven Stata programs for the calculation of sample size, number of events, and trial duration for a novel type of clinical trial design with a time-to-event outcome and two or more experimental arms. The approach is based oil terminating accrual of patients to inferior experimental treatment; arms at all early stage in the trial, allowing through to the next stage only treatments that show a predefined degree of advantage against the control treatment. The first stage of testing uses an intermediate outcome measure for the definitive (primary) outcome rather than with the primary outcome itself. The experimental arms are compared pairwise with the control arm according to the intermediate outcome measure. Arms that survive the comparison enter the next stage of patient accrual, culminating in comparisons against control on the primary outcome measure. The features supported include unequal patient allocation, target hazard ratios that may differ from 1 under the mull hypothesis, and the ability to stop patient recruitment at a specified time after trial initiation. The computations of sample size and power are based on the asymptotic mean and variance of the log hazard-ratio under the null and alternative hypotheses. The overall operating characteristics are computed from the intermediate and final stage significance levels and power, and the correlation between the log hazard-ratios oil the intermediate and primary outcome measures at the different stages. We illustrate the approach with the design of a United Kingdom Medical Research Council six-arm trial ill prostate cancer in which the intermediate outcome is failure-free survival and the primary outcome is overall survival.
引用
收藏
页码:505 / 523
页数:19
相关论文
共 9 条
[1]
How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design - a reanalysis of 4 trials [J].
Barthel, F. M-S ;
Parmar, M. K. B. ;
Royston, P. .
TRIALS, 2009, 10
[2]
BOOKMAN MA, 2006, J CLIN ONCOL S, V24, P5002
[3]
Criteria for the validation of surrogate endpoints in randomized experiments [J].
Buyse, M ;
Molenberghs, G .
BIOMETRICS, 1998, 54 (03) :1014-1029
[4]
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6
[5]
Speeding up the evaluation of new agents in cancer [J].
Parmar, Mahesh K. B. ;
Barthel, Friederike M. -S. ;
Sydes, Matthew ;
Langley, Ruth ;
Kaplan, Rick ;
Eisenhauer, Elizabeth ;
Brady, Mark ;
James, Nicholas ;
Bookman, Michael A. ;
Swart, Ann-Marie ;
Qian, Wendi ;
Royston, Patrick .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (17) :1204-1214
[6]
Parmar MKB, 2002, LANCET, V360, P505
[7]
Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer [J].
Royston, P ;
Parmar, MKB ;
Qian, W .
STATISTICS IN MEDICINE, 2003, 22 (14) :2239-2256
[8]
ROYSTON P, DESIGNS CLI IN PRESS